If you enjoy this content, please share it with a colleague
Here are several updates in medical imaging contrast media agents. Two of the biggest news items were related to safety ...
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source ...
Bayer Healthcare is expanding its global distribution network for the Medrad Intego positron emission tomography (PET) Infusion System through a new distribution agreement with Comecer SPA. Through this agreement, Bayer and Comecer are providing customers with an integrated nuclear medicine solution – combining the clinical administration capabilities of Intego with the Comecer's protection technologies for PET/CT centers around the world.
Bayer HealthCare announced that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
June 8, 2012 — Bayer HealthCare announced the formation of a strategic partnership with Radimetrics Inc. that will offer U.S. healthcare professionals the industry’s first computed tomography (CT) dose management software portfolio to include radiation and contrast dose tracking. Through the agreement, Bayer will distribute the Radimetrics eXposure Radiation Dose Management (RDM) software in addition to Bayer’s existing contrast-focused dose management solution.
June 8, 2012 — Bayer Radiology and Interventional has announced the introduction of the Certegra Workstation, an informatics-driven, touch-screen hub that enables time savings and improved patient care through a suite of CT (computed tomography) Contrast Dose Management applications and a new P3T 2.0 operating environment.
May 30, 2012 — Bayer Radiology & Interventional will showcase new device technologies at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami, June 9-13. The new technology includes enhancements to the Intego PET (positron emission tomography) Infusion System.
Two next-generation automated contrast injector systems were recently introduced in the United States.
April 16, 2012 — Piramal Healthcare Ltd. has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG through its newly created subsidiary, Piramal Imaging SA. The portfolio includes rights to florbetaben, which is in the final stages of its Phase III clinical trials.
Several positron emission tomography (PET) imaging agents are being developed to visualize Alzheimer’s disease in the living brain to accurately diagnose patients and develop effective treatments. The only way to confirm the presence of the disease currently is by examining post-mortem samples of the patient’s brain. Experts predict these agents may soon receive U.S. Food and Drug Administration (FDA) clearance.